• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Liraglutide and Robust A1C Reductions Among People With Type 2 Diabetes Requiring Appetite Control: A Review of Two Cases.利拉鲁肽与需要控制食欲的2型糖尿病患者的显著糖化血红蛋白降低：两例病例回顾
Diabetes Spectr. 2024 Spring;37(2):175-179. doi: 10.2337/ds23-0052. Epub 2023 Dec 14.
2
Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.降糖疗法的疗效及基线糖化血红蛋白 (A1C) 的影响：利拉鲁肽研发项目的荟萃分析。
Endocr Pract. 2011 Nov-Dec;17(6):906-13. doi: 10.4158/ep.17.6.906.
3
Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus.利拉鲁肽对2型糖尿病超重和肥胖患者身体成分、食欲依从性及血脂水平的24周影响。
Patient Prefer Adherence. 2016 Mar 24;10:407-13. doi: 10.2147/PPA.S97383. eCollection 2016.
4
Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States.美国开始使用利拉鲁肽治疗的2型糖尿病患者血糖控制及糖尿病相关费用的预测因素。
J Med Econ. 2016;19(4):403-13. doi: 10.3111/13696998.2015.1131703. Epub 2016 Jan 8.
5
Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes.利拉鲁肽相较于其他基于肠促胰岛素的疗法在 2 型糖尿病中的改善真实世界血糖结局。
Diabetes Obes Metab. 2014 Sep;16(9):819-26. doi: 10.1111/dom.12285. Epub 2014 Mar 25.
6
Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes.利拉鲁肽对 1 型糖尿病超重患者食物摄入、食欲感觉和进食行为的影响。
Diabetes Obes Metab. 2020 Aug;22(8):1417-1424. doi: 10.1111/dom.14050. Epub 2020 May 6.
7
Comparison of the Effectiveness of Liraglutide vs Semaglutide in a Veteran Population.利拉鲁肽与司美格鲁肽在退伍军人人群中的疗效比较。
J Pharm Pract. 2023 Oct;36(5):1095-1101. doi: 10.1177/08971900221087127. Epub 2022 Apr 12.
8
Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.利拉鲁肽序贯强化二甲双胍治疗 2 型糖尿病，根据 A1C 目标值随机加用基础胰岛素。
Diabetes Care. 2012 Jul;35(7):1446-54. doi: 10.2337/dc11-1928. Epub 2012 May 14.
9
Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States.口服司美格鲁肽治疗美国 2 型糖尿病的短期成本效益分析。
J Manag Care Spec Pharm. 2021 Jul;27(7):840-845. doi: 10.18553/jmcp.2021.27.7.840.
10
Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.当在基线 A1C<8.0%的 2 型糖尿病患者中添加二甲双胍时，利拉鲁肽比西格列汀或艾塞那肽更常达到 A1C 目标。
Endocr Pract. 2013 Jan-Feb;19(1):64-72. doi: 10.4158/EP12232.OR.

本文引用的文献

1
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.9. 血糖治疗的药物学方法：2023 年糖尿病的护理标准。
Diabetes Care. 2023 Jan 1;46(Suppl 1):S140-S157. doi: 10.2337/dc23-S009.
2
2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023.2. 糖尿病的分类和诊断：2023 年糖尿病护理标准。
Diabetes Care. 2023 Jan 1;46(Suppl 1):S19-S40. doi: 10.2337/dc23-S002.
3
Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.度拉糖肽治疗 2 型糖尿病的临床疗效及应答预测因素。
Pharmacol Res. 2020 Sep;159:104996. doi: 10.1016/j.phrs.2020.104996. Epub 2020 Jun 20.
4
Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study.度拉糖肽可减少伴有暴饮暴食症的2型糖尿病患者的暴饮暴食发作：一项试点研究。
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):289-292. doi: 10.1016/j.dsx.2020.03.009. Epub 2020 Mar 31.
5
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - .美国临床内分泌医师协会和美国内分泌学会关于2型糖尿病综合管理算法的共识声明 -
Endocr Pract. 2020 Jan;26(1):107-139. doi: 10.4158/CS-2019-0472.
6
Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus.2型糖尿病患者管理中降低心血管风险的进展
Chronic Dis Transl Med. 2019 Mar 15;5(1):25-36. doi: 10.1016/j.cdtm.2019.01.001. eCollection 2019 Mar.
7
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.强化血糖控制对 2 型糖尿病患者微血管结局的影响：来自随机对照试验的个体参与者数据的荟萃分析。
Lancet Diabetes Endocrinol. 2017 Jun;5(6):431-437. doi: 10.1016/S2213-8587(17)30104-3. Epub 2017 Mar 30.
8
Case Study: Use of GLP-1 Receptor Agonist in a Patient on Intensive Insulin Therapy.病例研究：胰高血糖素样肽-1受体激动剂在强化胰岛素治疗患者中的应用
Diabetes Spectr. 2015 May;28(2):121-6. doi: 10.2337/diaspect.28.2.121.
9
Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study.利拉鲁肽治疗3个月后非糖尿病肥胖个体暴饮暴食情况的改善——一项初步研究。
Obes Res Clin Pract. 2015 May-Jun;9(3):301-4. doi: 10.1016/j.orcp.2015.03.005. Epub 2015 Apr 11.
10
GLP-1 receptor agonists: a review of head-to-head clinical studies.GLP-1 受体激动剂：头对头临床研究综述。
Ther Adv Endocrinol Metab. 2015 Feb;6(1):19-28. doi: 10.1177/2042018814559725.

Liraglutide and Robust A1C Reductions Among People With Type 2 Diabetes Requiring Appetite Control: A Review of Two Cases.

作者信息

Pitts Mason A, Griggs Ryanne H, Hall Macey R, Tankersley McKinley S, Johnson Jeremy L

机构信息

Southwestern Oklahoma State University College of Pharmacy, Weatherford, OK.

Stillwater Medical Center, Stillwater, OK.

出版信息

Diabetes Spectr. 2024 Spring;37(2):175-179. doi: 10.2337/ds23-0052. Epub 2023 Dec 14.

DOI:10.2337/ds23-0052
PMID:38756434
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11093766/
Abstract
摘要